Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) have become the first‐line treatment of choice for patients with NSCLC harboring EGFR‐sensitizing mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.